• About Us
  • Contact Us
  • Today Headline
  • Write for us
Today Headline
No Result
View All Result
  • breaking news today
    • Politics news
    • Sports
    • Science News & Society
  • Entertainment News
    • Movie
    • Gaming
  • Technology News
    • Automotive
    • Software & IT
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
  • breaking news today
    • Politics news
    • Sports
    • Science News & Society
  • Entertainment News
    • Movie
    • Gaming
  • Technology News
    • Automotive
    • Software & IT
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
No Result
View All Result
TodayHeadline
No Result
View All Result

Axicabtagene ciloleucel approved for second-line treatment of large B-cell lymphoma

April 16, 2022
in Health News
Reading Time: 2 mins read
axicabtagene ciloleuce – TodayHeadline


Axicabtagene ciloleucel approved for second-line treatment of LBCL

Axicabtagene ciloleucel (axi-cel; Yescarta) was approved for treatment of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy, the U.S. Food and Drug Administration announced April 1.

The approval of this chimeric antigen receptor (CAR) T-cell therapy offers an alternative to the standard of care for LBCL, a multistep process that starts with chemoimmunotherapy and then involves high-dose chemotherapy and a stem cell transplant for patients who respond to and can tolerate further treatment. CAR T-cell therapies are made from a patient’s white blood cells (T cells), which are removed and sent to a specialized manufacturing facility to be engineered to treat the patient’s cancer and are then infused back into the patient. Physicians and patients can begin accessing Yescarta T-cell therapy through authorized treatment centers in the United States.

The FDA based its approval on data from ZUMA-7, a randomized, open-label, multicenter trial of 359 patients with primary refractory LBCL or relapse within one year after completion of first-line therapy. Researchers randomly assigned patients to a single infusion of axi-cel following fludarabine and cyclophosphamide lymphodepleting chemotherapy or to second-line chemotherapy consisting of two or three cycles of chemoimmunotherapy followed by high-dose therapy and autologous hematopoietic stem cell transplantation in patients who attained complete or partial remission.

Patients in the axi-cel arm achieved significantly longer event-free survival (hazard ratio, 0.40), with an estimated 18-month event-free survival rate of 41.5 percent compared with 17.0 percent in the standard therapy arm. Estimated median event-free survival was 8.3 and 2.0 months in the axi-cel and standard therapy arms, respectively.

The prescribing information for axi-cel includes a boxed warning for cytokine release syndrome and neurologic toxicities. The most commonly reported adverse reactions have included cytokine release syndrome, fever, hypotension, encephalopathy, fatigue, tachycardia, headache, nausea, febrile neutropenia, diarrhea, musculoskeletal pain, infections, chills, and decreased appetite.

Approval was granted to Kite Pharma Inc.


Axi-cel proves effective as first-line treatment for high-risk lymphoma


More information:
FDA Approval

© 2022 HealthDay. All rights reserved.

Citation:
Axicabtagene ciloleucel approved for second-line treatment of large B-cell lymphoma (2022, April 15)
retrieved 15 April 2022
from https://medicalxpress.com/news/2022-04-axicabtagene-ciloleucel-second-line-treatment-large.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

  • Trending
  • Comments
  • Latest
GettyImages 1411799498 scaled – TodayHeadline

Seven easy April Fools’ pranks for kids to play on parents

super73 adventure series header – TodayHeadline

SUPER73 announces new electric bikes, fast charging motorcycle

1a3732be 81a5 4ee5 9239 b6821a0ee504 – TodayHeadline

YMTC set for chip comeback despite US export controls

ff590a10 d52e 427b bbab 2be5a91f5e24 – TodayHeadline

AI will not remedy all our real estate woes

f 150 lightning platinum – TodayHeadline

Ford F-150 Lightning Prices Increase Again

Report – Economics Bitcoin News – TodayHeadline

Report – Economics Bitcoin News

6428c85272b7290018d22c2c – TodayHeadline

Stormy Daniels Was Riding Horse Redemption When Trump’s Indictment Was Reported

HollywoodSIgn229388 H 2022 – TodayHeadline

CEO Bob Rosenthal Resigns From Formosa Group – The Hollywood Reporter

PopularStories

f 150 lightning platinum – TodayHeadline
Automotive

Ford F-150 Lightning Prices Increase Again

Report – Economics Bitcoin News – TodayHeadline
Money

Report – Economics Bitcoin News

6428c85272b7290018d22c2c – TodayHeadline
Finance News

Stormy Daniels Was Riding Horse Redemption When Trump’s Indictment Was Reported

HollywoodSIgn229388 H 2022 – TodayHeadline
Movie

CEO Bob Rosenthal Resigns From Formosa Group – The Hollywood Reporter

About Us

Todayheadline the independent news and topics discovery
A home-grown and independent news and topic aggregation . displays breaking news linking to news websites all around the world.

Follow Us

Latest News

f 150 lightning platinum – TodayHeadline

Ford F-150 Lightning Prices Increase Again

Report – Economics Bitcoin News – TodayHeadline

Report – Economics Bitcoin News

6428c85272b7290018d22c2c – TodayHeadline

Stormy Daniels Was Riding Horse Redemption When Trump’s Indictment Was Reported

f 150 lightning platinum – TodayHeadline

Ford F-150 Lightning Prices Increase Again

Report – Economics Bitcoin News – TodayHeadline

Report – Economics Bitcoin News

6428c85272b7290018d22c2c – TodayHeadline

Stormy Daniels Was Riding Horse Redemption When Trump’s Indictment Was Reported

  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2023 All rights are reserved Today headline

No Result
View All Result
  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2023 All rights are reserved Today headline

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.